March 2018

Editorial Board
Published in issue: March 2018
i

EASL NAFLD Summit 2018, Geneva, Switzerland
Published in issue: March 2018
ii

EASL monothematic conference: Gut–liver axis, Leuven, Belgium, 2018
Published in issue: March 2018
iii

EASL membership
Published in issue: March 2018
iv

The International Liver Congress^TM, Paris, France, 2018
Published in issue: March 2018
v

Contents
Published in issue: March 2018
vii-ix

Discover the EASL app collection
Published in issue: March 2018
x

From the Editor's Desk

From the Editor’s desk...
March 2018
• Richard Moreau,
• Ramon Bataller,
• Thomas Berg,
• Jessica Zucman-Rossi,
• Rajiv Jalan
Published in issue: March 2018
p377-379

JHEP at a Glance

JHEP at a glance (March 2018)
Published in issue: March 2018
e1-e15

Editorials

Early liver transplantation for alcoholic hepatitis: Ready for primetime?
• Maddie Kubiliun,
• Suraj J. Patel,
• Chin Hur,
• Jules L. Dienstag,
• Jay Luther
Published online: November 23, 2017
p380-382
Achieving hepatitis C elimination in Europe – To treatment scale-up and beyond
• M. Hellard,
• N. Scott,
• R. Sacks-Davis,
• A. Pedrana
Published online: December 09, 2017
p383-385

Inhibition of hepatitis B virus gene expression: A step towards functional cure
• Fabien Zoulim
Published online: December 04, 2017
p386-388
Managing excessive alcohol consumption at a population level: The earlier the better
• Alexandre Louvet,
• Aleksander Krag
Published online: January 22, 2018
p389-390
Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name....
• Stephen Caldwell,
• Giulio Marchesini
Published online: December 13, 2017
p391-392

Research Articles

Viral Hepatitis


The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: An international study
• Maryam Alavi,
• Naveed Z. Janjua,
• Mei Chong,
• ...
• David J. Goldberg,
• Sharon J. Hutchinson,
• Gregory J. Dore
Published online: October 26, 2017
p393-401

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
• Hannah Fraser,
• Natasha K. Martin,
• Henrikki Brummer-Korvenkontio,
• ...
• Ruth Zimmermann,
• Peter Vickerman,
• Matthew Hickman
Published online: October 25, 2017
p402-411
Open Access

A novel orally available small molecule that inhibits hepatitis B virus expression
• Henrik Mueller,
• Steffen Wildum,
• Souphalone Luangsay,
• ...
• Song Yang,
• John A.T. Young,
• Hassan Javanbakht
Published online: October 25, 2017
p412-420
Open Access

Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis
• Julia Pollmann,
• Jana-Julia Götz,
• Daniel Rupp,
• ...
• Robert Thimme,
• Ralf Bartenschlager,
• Adelheid Cerwenka
Published online: October 31, 2017
p421-430

Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B
• Harry L.A. Janssen,
• Maurizia R. Brunetto,
• Yoon Jun Kim,
• ...
• Naoky C.S. Tsai,
• Scott Fung,
• Edward J. Gane
Published online: November 02, 2017
p431-440

The chaperone dynein LL1 mediates cytoplasmic transport of empty and mature hepatitis B virus capsids
• Quentin Osseman,
• Lara Gallucci,
• Shelly Au,
• ...
• Fenja Anderson,
• Nelly Panté,
• Michael Kann
Published online: November 04, 2017
p441-448

Cirrhosis


Pediatric CLIF-SOFA score is the best predictor of 28-day mortality in children with decompensated chronic liver disease
• Rishi Bolia,
• Anshu Srivastava,
• Surender Kumar Yachha,
• Ujjal Poddar
Published online: October 09, 2017
p449-455

Transplantation


The UK DCD Risk Score: A new proposal to define futility in donation-after-circulatory-death liver transplantation
• Andrea Schlegel,
• Marit Kalisvaart,
• Irene Scalera,
• ...
• John Isaac,
• Philipp Dutkowski,
• Paolo Muiesan
Published online: November 15, 2017
p456-464

Cancer


Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma
• Chaobo Hu,
• Weiping Li,
• Feng Tian,
• ...
• Yuan Ji,
• Junhao Hu,
• Lijian Hui
Published online: November 04, 2017
p465-475

Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study
• Gyuri Kim,
• Suk-Yong Jang,
• Chung Mo Nam,
• Eun Seok Kang
Published online: October 26, 2017
p476-484

Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules
• Eleonora Terzi,
• Massimo Iavarone,
• Maurizio Pompili,
• ...
• Stephanie R. Wilson,
• Fabio Piscaglia
• CEUS LI-RADS Italy study group collaborators:
Published online: November 10, 2017
p485-492

Molecular and Cell Biology


Gα₁₂ overexpression induced by miR-16 dysregulation contributes to liver fibrosis by promoting autophagy in hepatic stellate cells
• Kyu Min Kim,
• Chang Yeob Han,
• Ji Young Kim,
• ...
• Se Jin Hwang,
• Sung Hwan Ki,
• Sang Geon Kim
Published online: October 25, 2017
p493-504

Genetic and Metabolic Diseases


Alcohol consumption in late adolescence is associated with an increased risk of severe liver disease later in life
• Hannes Hagström,
• Tomas Hemmingsson,
• Andrea Discacciati,
• Anna Andreasson
Published online: January 22, 2018
p505-510

Application of prognostic scores in the STOPAH trial: Discriminant function is no longer the optimal scoring system in alcoholic hepatitis
• Ewan H. Forrest,
• Stephen R. Atkinson,
• Paul Richardson,
• ...
• Mark R. Thursz,
• Michael Allison
• On behalf of the STOPAH trial Management Group
Published online: November 21, 2017
p511-518

Is cryptogenic cirrhosis different from NASH cirrhosis?
• Paul J. Thuluvath,
• Sergey Kantsevoy,
• Avesh J. Thuluvath,
• Yulia Savva
Published online: November 20, 2017
p519-525

Reviews

Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
• Naoto Fujiwara,
• Scott L. Friedman,
• Nicolas Goossens,
• Yujin Hoshida
Published online: October 06, 2017
p526-549

Hedgehog signalling in liver pathophysiology
• Mariana Verdelho Machado,
• Anna Mae Diehl
Published online: October 26, 2017
p550-562

Clinical states of cirrhosis and competing risks
• Gennaro D'Amico,
• Alberto Morabito,
• Mario D'Amico,
• ...
• Giuseppe Malizia,
• Paola Rebora,
• Maria Grazia Valsecchi
Published online: October 27, 2017
p563-576

Special Sections

Public Health


Access to care in rare liver diseases: New challenges and new opportunities
• David E.J. Jones,
• Ekkehard Sturm,
• Ansgar W. Lohse
Published online: November 04, 2017
p577-585

Controversies in Hepatology

Controversies in clinical trials for alcoholic hepatitis
• Sarah R. Lieber,
• John P. Rice,
• Michael R. Lucey,
• Ramon Bataller
Published online: September 28, 2017
p586-592

Hepatology Snapshot

The many-faced role of autophagy in liver diseases
• Jordi Gracia-Sancho,
• Sergi Guixé-Muntet
Published online: January 16, 2018
p593-594

Letters to the Editor

Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world
• Philippe Halfon,
• Caroline Scholtès,
• Jacques Izopet,
• ...
• Laurent Chiche,
• Marc Bourlière,
• Florence Abravanel
Published online: October 05, 2017
p595-597

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?
• Velia Chiara Di Maio,
• Valeria Cento,
• Marianna Aragri,
• ...
• Carlo Federico Perno,
• Francesca Ceccherini-Silberstein
• on behalf of treatment team of the HCV Virology Italian Resistance Network (VIRONET-C)
Published online: September 19, 2017
p597-600

Primary prophylaxis of oesophageal variceal bleeding in children by ligation is safe and as efficient as secondary prophylaxis
• Julie Galand,
• Delphine Ley,
• Stéphanie Coopman,
• ...
• Dominique Guimber,
• Dominique Turck,
• Frédéric Gottrand
Published online: September 25, 2017
p600-601
Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM^VCTE algorithm
• Xiao-Chen Wang,
• Xiao-Yu Zhang,
• Xin Zhang,
• ...
• Jin-Cheng Wang,
• Beicheng Sun,
• Xiao-Jie Lu
Published online: October 06, 2017
p602-603

Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes
• Jean-Michel Petit,
• Benjamin Bouillet,
• Romaric Loffroy,
• Alexias Rouland,
• Patrick Hillon,
• Bruno Verges
Published online: October 05, 2017
p603-604
Reply to: “Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM^VCTE algorithm” and to “Application of the new eLIFT test for the non-invasive diagnosis of advanced liver fibrosis in people with type 2 diabetes”
• Jérôme Boursier,
• Victor de Ledinghen,
• Vincent Leroy,
• Paul Calès
Published online: October 05, 2017
p605-606
Imaging basis of AFP and WFA⁺M2BP as indicators of the risk of HCC after SVR
• Hidenori Toyoda,
• Takashi Kumada,
• Toshifumi Tada,
• Kazuyuki Mizuno
Published online: October 25, 2017
p606-607
Reply to: “Imaging Basis of AFP and WFA⁺M2BP as Indicators of the risk of HCC after SVR”
• Hiroko Nagata,
• Mina Nakagawa,
• Yasuhiro Asahina
Published online: October 25, 2017
p607-608

Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
• Yiqi Yu,
• Jing Wang,
• Guojun Li,
• ...
• Jiming Zhang,
• Chao Qiu,
• Wenhong Zhang
Published online: October 06, 2017
p609-610
Reply to: “Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?”
• Thomas Berg,
• Jörg Petersen
• on behalf of the FINITE [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B] study authors
Published online: October 06, 2017
p611-612
Herbal tea consumption and the liver – All is not what it seems!
• Cyriac Abby Philips,
• Philip Augustine
Published online: October 05, 2017
p612-613
Reply to: “Herbal tea consumption and the liver – All is not what is seems!”
• Louise J.M. Alferink,
• Jessica C. Kiefte-de Jong,
• Sarwa Darwish Murad
Published online: October 03, 2017
p613-614
Direct antiviral agents and risk of HCC: Waiting for Godot
• Calogero Cammà,
• Gioacchino Leandro
Published online: October 09, 2017
p614-616
Reply to: “Direct antiviral agents and risk of HCC: Waiting for Godot”
• Reem Waziry,
• Janaki Amin,
• Matthew Law,
• Gregory J. Dore
Published online: October 09, 2017
p616-617
Acid-base disorders in liver disease
• Anna Teresa Mazzeo,
• Sergio Maimone
Published online: October 20, 2017
p617-618